The 1st Psoriasis Symposium, organised by the Psoriasis Association of Bosnia and Herzegovina in collaboration with the Skin Inflammation & Psoriasis International Network (SPIN), the International Society of Dermatology and the European Academy of Dermatology and Venerology, was held in Sarajevo on 13-15 October 2017.
The Symposium was intended to provide delegates with the latest research and facts on diagnoses and genetics of psoriasis and psoriatic arthritis, long-term treatment with available therapies and treatments in development.
Approximately 200 participants and 40 guests from 22 countries across three continents participated in the Symposium.
The Symposium’s scientific programme included lectures by 26 international invited speakers, with the aim of presenting contemporary achievements in psoriasis and exchanging experiences.
There were 46 lectures and 21 poster presentations as well as 5 sponsored satellite symposia.
The main topics of the Symposium were:
- Immune system and psoriatic disease
- Psoriasis as a systemic disease
- Psoriasis in childhood and pregnancy
- Clinical and diagnostic characteristics of psoriasis and psoriatic arthritis
- Psoriasis therapy: from conventional therapies to biological drugs
- Free themes
As a partner organization, SPIN organized a session during this meeting.
Following the welcome and introductory speeches of SPIN Chair Professor Jo Lambert, lectures were held by the members of the SPIN Scientific Committee:
- Prof. Nejib Doss, Tunisia: Nail psoriasis: differential diagnosis
- Prof. Christopher Griffiths, UK: Systems medicine and psoriasis management
- Prof. Romana Ceovoc, Croatia: Topical treatments and phototherapy in the era of biologics
- Prof. Thomas A. Luger, Germany: Novel therapies for psoriasis: where are we going?
- Prof. Jo Lambert, Belgium: Tailored prescribing of biologicals: a challenge for the near future.
That event was also marked by the celebration of World Psoriasis Day - a day for awareness and advocacy for all people living with psoriasis and psoriatic arthritis around the world!
Rich cultural and social programs and the unique multicultural spirit and historical heritage of Sarajevo city have contributed to the good mood of all participants wishing to meet again and to exchange some new experiences.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Uncovering the mechanism of Jueyin granules in the treatment of psoriasis using network pharmacology.
J Ethnopharmacol.
2020 Nov 15, 262:113214.
Our clinical practice demonstrated that Jueyin granules (JYG) benefit patients with mild to moderate psoriasis vulgaris without apparent adverse effects. JYG have been shown to inhibit epidermal proliferation in an imiquimod (IMQ)-induced psoriasis-like mouse model, as well as keratinocyte proliferation. Moreover, JYG causes no acute or chronic toxicity in animal models. However, its related molecular mechanism has still not been (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
In silico data mining of large-scale databases for the virtual screening of human interleukin-2 inhibitors.
Acta Pharm.
2021 Mar 01, 71, (1):33-56.
Interleukin-2 (IL-2) is involved in the activation and differentiation of T-helper cells. Uncontrolled activated T cells play a key role in the pathophysiology by stimulating inflammation and autoimmune diseases like arthritis, psoriasis and Crohn's disease. T cells activation can be suppressed either by preventing IL-2 production or blocking the IL-2 interaction with its receptor. Hence, IL-2 is now emerging as a target for novel therapeutic approaches in several autoimmune disorders. This (...)
see on pubmed
on Atopic Dermatitis
Enhanced Type 2 Immune Reactions by Increased IL-22/IL-22Ra1 Signaling in Chronic Rhinosinusitis With Nasal Polyps.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):980-993.
Recent studies have revealed the pathogenic role of interleukin (IL)-22 in atopic dermatitis and asthma. However, little is known about the role of IL-22 in the pathophysiology of chronic rhinosinusitis with nasal polyps. We aimed to investigate the expression of IL-22 and its pathogenic function in type 2 immune reactions of nasal polyps (NP).
see on pubmed
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Seok SH et al.
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):1063-1065.
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
